The Autoimmune Protocol (AIP) in Medical Research
A Comprehensive Review of Published Studies and Findings
The Autoimmune Protocol (AIP) has rapidly evolved from a community-driven dietary approach to an intervention increasingly evaluated in clinical settings. Over the past decade, published studies have examined AIP across multiple autoimmune diseases—including inflammatory bowel disease, Hashimoto’s thyroiditis, rheumatoid arthritis, and psoriasis—and the results point consistently toward meaningful improvements in symptoms, inflammation, quality of life, and even immune regulation at the tissue level. While the research is still early, the emerging evidence provides an important foundation for understanding how AIP may support autoimmune care.
What You’ll Learn in This Article:
- Findings from clinical studies in inflammatory bowel disease (Crohn’s disease and ulcerative colitis)
- Evidence on symptom burden, inflammation, nutrient density, and thyroid health in Hashimoto’s thyroiditis
- Qualitative and pilot intervention data on rheumatoid arthritis
- Early insights from AIP research in eczema psoriasis
- Forthcoming studies exploring AIP in additional autoimmune and inflammatory conditions like myasthenia gravis and kidney disease
- Answers to frequently asked questions about the AIP medical research
From Anecdote to Evidence
When people first hear about the Autoimmune Protocol (AIP), it’s often through personal healing stories shared in communities, books, or online groups. These stories are powerful—they offer hope, validation, and a sense of connection. But in medicine, anecdotal experiences alone aren’t considered evidence. What truly shifts understanding is when those experiences are tested under controlled conditions and measured in ways that patients, providers, and researchers can trust.
Over the past decade, that shift has begun to happen. AIP has gained the attention of clinical researchers, leading to a growing body of published studies. The first pilot trial launched in 2015, and since then the protocol has been formally evaluated in individuals with inflammatory bowel disease (IBD), Hashimoto’s thyroiditis, rheumatoid arthritis, and psoriasis. Additional studies are now in development, extending this work into less common autoimmune and inflammatory conditions.
While the research is still early—most trials are small and preliminary—the findings are consistently promising. Across diseases, participants report meaningful improvements in symptoms, reductions in inflammation, better quality of life, and, in some cases, clinical remission. For patients who have long been told that diet and lifestyle interventions offer little benefit, this growing evidence represents a remarkable and hopeful turning point.
AIP and Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis)
Pilot Study: Clinical Efficacy (Konijeti et al., 2017)
The first formal AIP study, conducted by Dr. Gauree Konijeti and her team at Scripps San Diego, evaluated 15 patients with active Crohn’s disease or ulcerative colitis. These were not mild cases—participants had an average disease duration of 19 years, and nearly half were on biologic therapy without achieving remission.
Intervention:
Participants completed a 6-week staged elimination (removing two food groups at a time while increasing nutrient density), followed by 5 weeks of full AIP elimination. Support was provided through a group health coaching model.
Results:
- 73% of participants achieved clinical remission by week 6.
- All maintained remission through week 11.
- Four participants reduced or discontinued medication.
- Remission occurred during the transition phase, suggesting benefits may begin early in the process.
- Two participants with strictures experienced complications, highlighting the need for appropriate supervision.
Key Takeaways:
This pilot study offered the first clinical evidence that AIP may help induce remission in treatment-resistant IBD. While preliminary, the results demonstrated both feasibility and significant therapeutic potential, setting the stage for further research.
Explore a deeper breakdown of the remission outcomes and methods from this landmark IBD trial
Study on Quality of Life Outcomes (Chandrasekaran et al., 2019)
A follow-up analysis from the same Scripps San Diego cohort examined patient-reported outcomes using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). This study evaluated how AIP affected daily functioning, wellbeing, and overall quality of life among participants with Crohn’s disease and ulcerative colitis.
Intervention:
Participants completed the full AIP process as designed in the original trial: A 6-week staged elimination, removing two food groups at a time while increasing nutrient density, followed by 5 weeks of full AIP elimination. All participants received support through a group health coaching model.
Results:
- Baseline SIBDQ score: 46.5, indicating poor quality of life coming into the study
- After 11 weeks: 61.5, indicating improved quality of life
These improvements paralleled the high remission rates seen in the clinical efficacy study, providing insight into how patients felt—not just how their symptoms were measured.
Key Takeaways:
This study showed that AIP’s impact extends beyond clinical remission. Participants reported significant improvements in daily functioning and wellbeing, suggesting that AIP may enhance quality of life in addition to reducing disease activity.
Learn more about how AIP improved quality of life measures in this follow-up analysis
Study on Intestinal RNA Expression (Chandrasekaran et al., 2019)
A third analysis from the same Scripps San Diego cohort examined changes in intestinal RNA expression among participants with ulcerative colitis. This study explored how AIP may influence immune pathways and tissue-level inflammation at the molecular level.
Intervention:
Participants followed the full AIP protocol used throughout the trial: A 6-week staged elimination removing two food groups at a time while increasing nutrient density, Followed by 5 weeks of full AIP elimination. Biopsy samples collected before and after the intervention allowed researchers to analyze shifts in gene expression.
Results:
- Researchers identified 324 genes with significant changes in expression following the AIP intervention:
- 167 genes were downregulated, including many associated with pro-inflammatory T-cell responses
- 157 genes were upregulated, including those involved in immune regulation, mucosal healing, and DNA repair
These molecular changes aligned with the clinical improvements seen in the broader cohort.
Key Takeaways:
This study provided early mechanistic insight into how AIP may support healing in IBD. The protocol was associated with reduced inflammatory gene activity and increased markers of tissue repair, suggesting that dietary intervention may influence immune regulation at the cellular level.
Read the extended analysis of the gene expression changes associated with the AIP interventionSurvey on Long-Term AIP Use in IBD (Lee et al., 2019)
To understand how AIP performs outside of a clinical trial setting, researchers surveyed 78 individuals with Crohn’s disease or ulcerative colitis who had adopted the AIP diet on their own. This study captured real-world outcomes, sustainability, and common food triggers reported by long-term AIP users.
Intervention:
Participants self-implemented the Autoimmune Protocol, typically beginning with an elimination phase followed by gradual reintroductions. Unlike the clinical study, this survey did not involve coaching or structured monitoring, offering insight into everyday use of AIP in community settings.
Results:
- 73% of respondents reported achieving clinical remission
- 32% discontinued steroid medications
- Most participants successfully reintroduced foods within one year
Commonly reported food triggers included:
-
- Gluten (58%)
- Processed foods (52%)
- Nightshades (46%)
- Dairy (42%)
- Non-gluten grains (29%)
Key Takeaways:
This real-world data reaffirmed the clinical findings, showing that many individuals with IBD experience meaningful symptom improvement with AIP. The high rates of remission and reduction in steroid use suggest that AIP can be both effective and sustainable outside of supervised research environments.
Dive deeper into real-world AIP outcomes, food triggers, and long-term sustainability findingsAIP and Hashimoto’s Thyroiditis
Study on Symptom Burden and Inflammation (Abbott et al., 2019)
The first clinical evaluation of AIP for Hashimoto’s thyroiditis was conducted by Dr. Rob Abbott and colleagues. Seventeen women with Hashimoto’s participated in a 10-week intervention designed to assess changes in symptom burden, inflammation, and overall wellbeing. This study was notable for exploring AIP’s potential beyond gut-focused autoimmune diseases.
Intervention:
Participants completed a 6-week staged elimination, removing two food groups at a time while increasing nutrient density, followed by 4 weeks of full AIP elimination. Support was delivered through a multi-disciplinary model that included group health coaching.
Results:
- Symptom burden: (Medical Symptom Questionnaire): decreased from 92 → 29
- Systemic inflammation: hs-CRP decreased by 29%
- Medication adjustments: 6 of 13 participants lowered or discontinued thyroid hormone
- Thyroid markers: No significant changes in thyroid antibodies or hormone levels were observed
Key Takeaways:
This study demonstrated that AIP can significantly reduce symptom burden and systemic inflammation in Hashimoto’s thyroiditis, even when conventional thyroid markers remain stable. It highlighted AIP as a supportive lifestyle intervention that may complement, rather than replace, medical treatment.
Explore a full discussion of how AIP reduced symptoms and inflammation in Hashimoto’sStudy on Nutrient Density and Thyroid Health (Ihnatowicz et al., 2023)
A second clinical study, conducted in Poland, evaluated how AIP influences nutrient intake, thyroid parameters, and quality of life over a 12-week period. Twenty adults with Hashimoto’s completed the intervention, offering a more detailed look at how dietary quality shifts during AIP.
Intervention:
Participants followed a structured AIP elimination phase with nutritionist guidance throughout the full 12-week program, emphasizing increased nutrient density and whole-food patterns.
Results:
Thyroid hormones:
- TSH decreased from 3.72 → 2.69 mU/L
- Free T3 and T4 decreased slightly but remained within normal ranges
Thyroid ultrasound: Thyroid gland volume decreased by 5–6%
Anthropometrics:
- Weight decreased from 69 → 65.5 kg
- Body fat percentage decreased from 33% → 29.5%
Symptom improvement: Participants reported reductions in fatigue, brain fog, and skin symptoms
Nutrient density: Significant increases in beta-carotene, vitamin A, vitamin C, folate, fiber, and minerals
Key Takeaways:
This study underscored AIP’s role not only as an elimination protocol but as a nutrient-dense dietary pattern that may support thyroid health. Improvements in ultrasound findings, symptoms, and nutrient intake suggest AIP may influence multiple dimensions of wellbeing in Hashimoto’s.
Learn more about how AIP influences thyroid markers, nutrient intake, and ultrasound findingsAIP and Rheumatoid Arthritis
Qualitative Study on Patient Experience (Taylor, 2020)
The first research exploring AIP for rheumatoid arthritis (RA) focused on patient perspectives rather than clinical outcomes. PhD candidate Julianne Taylor interviewed individuals with RA who had successfully used AIP to manage symptoms. The study examined motivations, barriers, and factors that supported long-term adherence.
Intervention:
This was a qualitative interview study, not a structured dietary intervention. All participants had already implemented AIP independently and maintained it long enough to reflect on their experiences.
Results:
Participants consistently identified:
- Pain reduction as the main motivator for starting and sustaining AIP
- Barriers such as the restrictiveness of the diet and reduced social flexibility
- Supportive factors including practitioner guidance and encouragement from at least one supportive person in their life
Key Takeaways:
This study highlighted the real-world experiences of individuals with RA using AIP and underscored the roles of community support and practitioner involvement. It also pointed to common challenges that can inform how clinicians and educators introduce AIP to patients.
Read more about patient motivations, barriers, and lived experiences using AIP for RA
Pilot Intervention Study (McNeill et al., 2023)
A subsequent pilot trial led by McNeill and colleagues tested AIP as an intervention for rheumatoid arthritis using a mixed-methods design. While final publication is pending, preliminary findings were presented at the Nutrition Society Conference.
Intervention:
Participants completed a guided AIP elimination phase with structured support and symptom monitoring, followed by qualitative interviews to capture subjective experience.
Results:
Preliminary data indicated:
- Improvements in pain
- Reductions in fatigue
- Better sleep quality
- Enhanced overall quality of life
Full biomarkers and quantitative outcomes will be available upon publication.
Key Takeaways:
Although early, these findings suggest AIP may offer symptom relief and quality-of-life benefits for individuals with RA. The mixed-methods design strengthens the evidence base by combining measurable outcomes with patient experience.
See a deeper look at the mixed-methods findings and emerging clinical data for AIP in RA
AIP and Psoriasis
AIP Pilot Study in Psoriasis (Completed 2020; Publication Pending)
A clinical study evaluating AIP for psoriasis was completed in 2020. Although delays related to the COVID-19 pandemic postponed full publication, early reports from the research team provide encouraging insights.
Intervention:
Participants completed a structured AIP elimination with practitioner guidance, similar to earlier studies conducted for IBD and Hashimoto’s.
Results:
Preliminary accounts suggest:
- Improvements in skin lesion severity
- Enhanced quality of life and reduced symptom burden
- High participant engagement and feasibility of the protocol
More detailed outcomes will be available upon journal release.
Key Takeaways:
While final data are still forthcoming, early findings indicate that AIP may have therapeutic potential for psoriasis—a condition with strong immune and inflammatory components. This study also expands the scope of AIP research beyond gastrointestinal and endocrine diseases.
Forthcoming AIP Research
Ongoing and Planned Studies
The research landscape for AIP continues to grow, with several new studies underway or in development. These investigations aim to broaden understanding of how AIP may support autoimmune and inflammatory conditions beyond those already examined.
Areas of active development include:
- Myasthenia gravis (MG): A rare autoimmune neuromuscular condition causing muscle weakness. Planned studies will explore whether AIP can support symptom management or improve quality of life.
- Kidney disease: Researchers are preparing trials to test AIP in inflammatory kidney conditions, an area where dietary interventions are rarely studied but urgently needed.
Key Takeaways:
These upcoming studies highlight the expanding interest in AIP within the scientific community. As research grows, so does the potential to uncover how dietary and lifestyle interventions can complement traditional medical care across a broader range of autoimmune and inflammatory diseases.
Conclusion
In just over a decade, the Autoimmune Protocol (AIP) has progressed from a community-driven experiment to an emerging evidence-based intervention for autoimmune disease. Across multiple published studies, AIP has demonstrated meaningful, measurable benefits:
- Inflammatory Bowel Disease (IBD): AIP has induced clinical remission, improved quality of life, and even shifted gene expression linked to inflammation and tissue repair.
- Hashimoto’s Thyroiditis: Research shows reduced symptom burden, lower inflammatory markers, improvements in thyroid ultrasound findings, and increased nutrient density.
- Rheumatoid Arthritis (RA): Early trials and qualitative research report reductions in pain, fatigue, and overall symptom disruption, with additional studies underway.
- Psoriasis: While full results are pending, preliminary findings indicate improvements in skin lesion severity and wellbeing.
Although most existing studies are small pilot trials, this is precisely how meaningful scientific evaluation begins—by establishing feasibility, safety, and proof of concept. AIP has met those criteria consistently across multiple autoimmune conditions.
For patients, practitioners, and researchers alike, the takeaway is clear: the Autoimmune Protocol is no longer only anecdotal. It is supported by published evidence, clinically promising, and poised to play an increasingly important role in the future of autoimmune care.
Ready to take your first steps with AIP?
The free AIP Foundation Series gives you 60+ pages of downloadable materials, including Core & Modified AIP food lists, meal plans, and everything you need to begin your journey.
Frequently Asked Questions About AIP Research
Is the Autoimmune Protocol (AIP) evidence-based?
Yes. A growing number of published studies show that AIP can improve symptoms, reduce inflammation, enhance quality of life, and support clinical remission in several autoimmune conditions. While most studies are small pilot trials, they consistently demonstrate feasibility, safety, and meaningful benefit.
What autoimmune diseases have AIP studies?
AIP has been clinically studied in:
Additional trials are underway for conditions such as myasthenia gravis and inflammatory kidney disorders.
What does AIP research show about inflammation?
Multiple studies have found reductions in inflammatory markers, including hs-CRP in Hashimoto’s thyroiditis and inflammatory gene activity in IBD. These changes suggest AIP may help regulate immune pathways and calm systemic inflammation.
How long does it take to see results on AIP?
Many participants in clinical trials experienced improvements within 4–6 weeks, including reductions in pain, digestive symptoms, and fatigue. However, the full elimination and reintroduction process typically spans several months.
Is AIP safe to follow?
Studies to date indicate that AIP is generally safe when properly implemented. However, individuals with complex medical conditions—such as IBD strictures or nutrient deficiencies—should follow AIP under medical supervision.
Does the research support reintroducing foods?
Yes. Both clinical studies and survey data show that many participants successfully reintroduce foods over time. AIP is meant to be a short-term learning phase that leads to a personalized, sustainable long-term diet.
Are larger AIP studies planned?
Yes. Researchers are designing larger and longer-term studies to evaluate AIP in additional autoimmune and inflammatory conditions. These trials will help confirm early findings and further define AIP’s role in clinical care.
How does AIP compare to other diets used for autoimmune disease?
AIP is more structured and comprehensive than most elimination diets because it combines dietary changes with lifestyle practices that support immune regulation, gut health, and inflammation balance. Compared to approaches like Paleo, Whole30, or general anti-inflammatory diets, AIP is specifically designed for autoimmune conditions and includes a staged reintroduction process to help individuals identify personal food sensitivities. Clinical studies also provide early evidence for AIP’s effectiveness, which is not available for many other dietary frameworks.
What mechanisms do researchers believe explain AIP’s benefits?
Although research is still emerging, several potential mechanisms have been identified. Studies suggest that AIP may reduce intestinal inflammation, support mucosal healing, and promote a healthier gut microbiome. Gene expression research in IBD patients has shown downregulation of inflammatory pathways and upregulation of markers tied to immune regulation and tissue repair. Additionally, the emphasis on nutrient density, blood sugar balance, and lifestyle practices may help regulate immune function and reduce systemic inflammation.
What are the limitations of current AIP research?
Most AIP studies to date are small pilot trials, meaning sample sizes are limited and long-term outcomes are still being evaluated. Many studies rely on self-reported data, and standardized biomarkers vary across conditions. Because the research is early, results cannot yet be generalized to all autoimmune diseases or populations. Larger, longer-term, and more diverse trials are needed to confirm findings and better understand who benefits most from AIP.
Do participants in AIP studies work with healthcare providers?
Yes. Most published AIP studies involve multidisciplinary oversight, including physicians, nutritionists, and trained health coaches. Participants typically receive guidance on dietary changes, symptom tracking, and lifestyle practices. This collaborative approach ensures safety, improves adherence, and helps researchers monitor outcomes. AIP is intended to complement—not replace—professional medical care.
Is AIP effective for people who already take medication?
Research suggests that AIP can be beneficial alongside conventional treatments. In the IBD and Hashimoto’s studies, many participants were already on medications such as biologics or thyroid hormone. Some experienced improved symptoms or were able to reduce medication doses under medical supervision. AIP is not a substitute for necessary treatment, but it may enhance overall disease management and help patients achieve better outcomes in combination with their existing care plan.
